Xconomy Forum

Reinventing Biotech’s Business Model

Biotech companies used to think about how to build enduring companies with soup-to-nuts operations that had everything under one corporate flag, from research to development to manufacturing to marketing. Those models increasingly look like relics. Investors have grown weary of the long timelines, big bucks, and high risk that comes with building such organizations. Stung by losses, a number of VCs, entrepreneurs and investors are turning to small core teams that lean heavily on contract firms to try to make biotech more nimble, less capital intensive, and a more attractive industry for investment. Come join Xconomy for a number of case studies and interactive chats with national leaders who are looking to reinvent the biotech business model.

Confirmed Speakers

Corey Goodman
- Partner, venBio
John Maraganore
- CEO, Alnylam Pharmaceuticals
Kevin Starr
- Partner, Third Rock Ventures
Kathy Glaub
- President, Plexxikon
Carl Weissman
- CEO, Accelerator
Thong Le
- Managing Director, WRF Capital
Carol Gallagher
- former CEO, Calistoga Pharmaceuticals
Bruce Montgomery
- CEO, Cardeas Pharma
Heather Franklin
- CEO, Blaze Bioscience
Peppi Prasit
- Founder, Inception Sciences
David McElligott
- CSO, Groove Biopharma
Steve Tregay
- CEO, Forma Therapeutics
Brian Atwood
- Managing Director, Versant Ventures
Alex Lash
- Biopharma editor, Start-Up, In Vivo
Ed Saltzman
- President, Defined Health

Schedule

Registration: 1:00 – 2:00 pm
Program: 2:00 – 6:00 pm
Networking Reception: 6:00 – 7:00 pm

Registration Information

Super Saver Rate (ends Feb. 1) $125
Startup Special $95 (for employees of startups less than 3 years old with 20 or fewer employees)
Regular Registration $195
Student Registration $30
Walk-in Registration $275

EVENT HOST